Skip to Content
Merck
  • Influence of dTMP on the phenotypic appearance and intracellular persistence of Staphylococcus aureus.

Influence of dTMP on the phenotypic appearance and intracellular persistence of Staphylococcus aureus.

Infection and immunity (2007-12-28)
Johannes Zander, Silke Besier, Stephan H Saum, Faramarz Dehghani, Stefan Loitsch, Volker Brade, Thomas A Wichelhaus
ABSTRACT

Thymidine-dependent small-colony variants (SCVs) of Staphylococcus aureus are frequently associated with persistent and recurrent infections in cystic fibrosis patients. The phenotypic appearance of S. aureus SCVs or normal-colony variants (NCVs) is postulated to be affected by the intracellular amount of dTMP. This hypothesis was proven by metabolic pathway assays revealing altered intracellular dTMP concentrations, followed by investigation of the associated phenotype. Inhibition of the staphylococcal thymidylate synthase, which generated intracellular dTMP from dUMP, using 5-fluorouracil and co-trimoxazole resulted in an SCV phenotype. Inhibition of a nucleoside transporter, which provided the bacterial cell with extracellular thymidine, caused growth inhibition of SCVs. In turn, reversion of SCVs to NCVs was achieved by supplying extracellular dTMP. High-performance liquid chromatography additionally confirmed the intracellular lack of dTMP in SCVs, in contrast to NCVs. Moreover, the dTMP concentration is postulated to influence the intracellular persistence of S. aureus. Cell culture experiments with cystic fibrosis cells revealed that clinical and co-trimoxazole-induced SCVs with a diminished amount of dTMP showed significantly better intracellular persistence than NCVs. In conclusion, these results show that the dTMP concentration plays a key role in both the phenotypic appearance and the intracellular persistence of S. aureus.

MATERIALS
Product Number
Brand
Product Description

Supelco
Erythromycin, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Thymidine, ≥99.0% (HPLC)
Sigma-Aldrich
Erythromycin, tested according to Ph. Eur.
Sigma-Aldrich
Phenylmethanesulfonyl fluoride, ≥99.0% (T)
Sigma-Aldrich
Phenylmethanesulfonyl fluoride, ≥98.5% (GC)
Sigma-Aldrich
Amphotericin B solubilized, powder, γ-irradiated, BioXtra, suitable for cell culture
Sigma-Aldrich
Thymidine, ≥99%
Sigma-Aldrich
Uridine, BioUltra, ≥99%
Sigma-Aldrich
Uridine, powder, BioReagent, suitable for cell culture
Sigma-Aldrich
Erythromycin, BioReagent, suitable for cell culture
Sigma-Aldrich
Erythromycin, potency: ≥850 μg per mg
Sigma-Aldrich
Erythromycin, meets USP testing specifications
Sigma-Aldrich
Thymidine, powder, BioReagent, suitable for cell culture
Sigma-Aldrich
Uridine, ≥99%
Sigma-Aldrich
Fluorouracil, meets USP testing specifications
Supelco
Fluorouracil, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
5-Fluorouracil, ≥99% (HPLC), powder
Sigma-Aldrich
Acetonitrile, ReagentPlus®, 99%
Sigma-Aldrich
Acetonitrile, suitable for DNA synthesis, ≥99.9% (GC)
Sigma-Aldrich
Acetonitrile, ACS reagent, ≥99.5%
Sigma-Aldrich
Acetonitrile, biotech. grade, ≥99.93%
Sigma-Aldrich
Lysostaphin from Staphylococcus simulans, recombinant, expressed in E. coli, lyophilized powder
Supelco
Chloramphenicol, VETRANAL®, analytical standard
Sigma-Aldrich
Acetonitrile, electronic grade, 99.999% trace metals basis
Supelco
Acetonitrile, analytical standard
Sigma-Aldrich
Chloramphenicol, meets USP testing specifications
Sigma-Aldrich
Amphotericin B solution, 250 μg/mL in deionized water, 0.1 μm filtered, BioReagent, suitable for cell culture
Sigma-Aldrich
Lysostaphin from Staphylococcus staphylolyticus, lyophilized powder, Protein 50-70 % by biuret, ≥500 units/mg protein
Sigma-Aldrich
Lysostaphin from Staphylococcus staphylolyticus, BioUltra, ≥97% (SDS-PAGE), Protein 40-60 % by biuret, ≥2,000 units/mg protein
Sigma-Aldrich
Lysostaphin from Staphylococcus staphylolyticus, aseptically filled